{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:19:23Z","timestamp":1792318763244,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0F8516N"],"award-info":[{"award-number":["G0F8516N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010648","name":"Universitaire Ziekenhuizen Leuven, KU Leuven","doi-asserted-by":"publisher","award":["C14-17-107"],"award-info":[{"award-number":["C14-17-107"]}],"id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","award":["Emil von Behring Chair for Neuromuscular and Neurodegenerative Disorders"],"award-info":[{"award-number":["Emil von Behring Chair for Neuromuscular and Neurodegenerative Disorders"]}],"id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s13760-020-01282-w","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T21:02:33Z","timestamp":1580245353000},"page":"355-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Myositis as a neuromuscular complication of immune checkpoint inhibitors"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3903-8466","authenticated-orcid":false,"given":"Lynn","family":"Vermeulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe E.","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Weckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar R.","family":"Thal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"6","key":"1282_CR1","first-page":"418","volume":"5","author":"KM Kreamer","year":"2014","unstructured":"Kreamer KM (2014) Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol 5(6):418\u2013431","journal-title":"J Adv Pract Oncol"},{"issue":"9","key":"1282_CR2","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384\u20133391. https:\/\/doi.org\/10.1172\/JCI80011","journal-title":"J Clin Invest"},{"issue":"8","key":"1282_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"4","key":"1282_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","volume":"42","author":"EJ Lipson","year":"2015","unstructured":"Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL (2015) Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 42(4):587\u2013600. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.05.013","journal-title":"Semin Oncol"},{"key":"1282_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27816","author":"S Sadreddini","year":"2018","unstructured":"Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, Aghebati-Maleki L (2018) Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. https:\/\/doi.org\/10.1002\/jcp.27816","journal-title":"J Cell Physiol"},{"issue":"3","key":"1282_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137(3):601\u2013609. https:\/\/doi.org\/10.1007\/s11060-018-2752-5","journal-title":"J Neurooncol"},{"key":"1282_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26070","author":"NA Kolb","year":"2018","unstructured":"Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, Hehir M (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.26070","journal-title":"Muscle Nerve"},{"issue":"2","key":"1282_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28(2):377\u2013385. https:\/\/doi.org\/10.1093\/annonc\/mdw558","journal-title":"Ann Oncol"},{"issue":"10","key":"1282_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"issue":"11","key":"1282_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"issue":"10","key":"1282_CR11","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Aure K, Szwebel TA, Kramkimel N, Lethrosne C, Bruch JF, Laly P, Cadranel J, Weiss N, Behin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Leonard-Louis S (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91(10):e985\u2013e994. https:\/\/doi.org\/10.1212\/WNL.0000000000006124","journal-title":"Neurology"},{"key":"1282_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira A, Loquai C, Pfohler C, Kahler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Turk M, Dummer R, Zimmer L, Schroder R, Heinzerling L (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.033","journal-title":"Eur J Cancer"},{"issue":"4","key":"1282_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1017\/S0317167100007939","volume":"36","author":"G Hunter","year":"2009","unstructured":"Hunter G, Voll C, Robinson CA (2009) Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 36(4):518\u2013520","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"1282_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, Park JH, Nakamura Y, Ihn H (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107(7):1055\u20131058. https:\/\/doi.org\/10.1111\/cas.12961","journal-title":"Cancer Sci"},{"issue":"3","key":"1282_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/annonc\/mdw655","volume":"28","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, Wijdicks EF, Goetz MP (2017) Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 28(3):673\u2013675. https:\/\/doi.org\/10.1093\/annonc\/mdw655","journal-title":"Ann Oncol"},{"issue":"7","key":"1282_CR16","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","volume":"27","author":"H Vallet","year":"2016","unstructured":"Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, Franck N, Kramkimel N, Borden A, Touat M, Ricard D, Verny M, Maisonobe T, Psimaras D (2016) Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 27(7):1352\u20131353. https:\/\/doi.org\/10.1093\/annonc\/mdw126","journal-title":"Ann Oncol"},{"key":"1282_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","volume":"105","author":"EL Mitchell","year":"2018","unstructured":"Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Ostor A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S (2018) Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer 105:88\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.027","journal-title":"Eur J Cancer"},{"issue":"4","key":"1282_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312\u2013318. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0237","journal-title":"Cancer Immunol Res"},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"issue":"1","key":"1282_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"1","key":"1282_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","volume":"18","author":"C Astaras","year":"2018","unstructured":"Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF (2018) Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 18(1):3. https:\/\/doi.org\/10.1007\/s11910-018-0810-1","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"1282_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806\u2013812. https:\/\/doi.org\/10.1097\/WCO.0000000000000391","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"1282_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","volume":"41","author":"T Liewluck","year":"2018","unstructured":"Liewluck T, Kao JC, Mauermann ML (2018) PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 41(4):208\u2013211. https:\/\/doi.org\/10.1097\/CJI.0000000000000196","journal-title":"J Immunother"},{"key":"1282_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.11.012","author":"A Puwanant","year":"2018","unstructured":"Puwanant A, Isfort M, Lacomis D, Zivkovic SA (2018) Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. https:\/\/doi.org\/10.1016\/j.nmd.2018.11.012","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1282_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/CJI.0000000000000178","volume":"40","author":"A Pushkarevskaya","year":"2017","unstructured":"Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, Hassel JC (2017) Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J Immunother 40(7):282\u2013285. https:\/\/doi.org\/10.1097\/CJI.0000000000000178","journal-title":"J Immunother"},{"issue":"6\u20137","key":"1282_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","volume":"140","author":"M Lecouflet","year":"2013","unstructured":"Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D, Martin L (2013) Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 140(6\u20137):448\u2013451. https:\/\/doi.org\/10.1016\/j.annder.2013.02.029","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"1282_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","volume":"138","author":"C Anquetil","year":"2018","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Leonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y (2018) Immune checkpoint inhibitor-associated myositis. Circulation 138(7):743\u2013745. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035898","journal-title":"Circulation"},{"issue":"1","key":"1282_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","volume":"46","author":"T Shirai","year":"2016","unstructured":"Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R, Uhara H (2016) Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46(1):86\u201388. https:\/\/doi.org\/10.1093\/jjco\/hyv158","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1282_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"issue":"10124","key":"1282_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"issue":"17","key":"1282_CR31","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA (2018) National Comprehensive Cancer Network Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"11","key":"1282_CR32","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","volume":"66","author":"S Suzuki","year":"2009","unstructured":"Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, Kuwana M, Suzuki N (2009) Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66(11):1334\u20131338. https:\/\/doi.org\/10.1001\/archneurol.2009.229","journal-title":"Arch Neurol"},{"issue":"11","key":"1282_CR33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/acn3.654","volume":"5","author":"K Takamatsu","year":"2018","unstructured":"Takamatsu K, Nakane S, Suzuki S, Kosaka T, Fukushima S, Kimura T, Miyashita A, Mukaino A, Yamakawa S, Watanabe K, Jinnin M, Komohara Y, Ihn H, Ando Y (2018) Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol 5(11):1421\u20131427. https:\/\/doi.org\/10.1002\/acn3.654","journal-title":"Ann Clin Transl Neurol"},{"key":"1282_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","volume":"4","author":"MA Bilen","year":"2016","unstructured":"Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P (2016) Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36. https:\/\/doi.org\/10.1186\/s40425-016-0139-8","journal-title":"J Immunother Cancer"},{"issue":"18","key":"1282_CR35","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"issue":"1","key":"1282_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","volume":"5","author":"S John","year":"2017","unstructured":"John S, Antonia SJ, Rose TA, Seifert RP, Centeno BA, Wagner AS, Creelan BC (2017) Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab-durvalumab treatment. J Immunother Cancer 5(1):54. https:\/\/doi.org\/10.1186\/s40425-017-0258-x","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1282_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/kex346","volume":"57","author":"PC Gandiga","year":"2018","unstructured":"Gandiga PC, Wang AR, Gonzalez-Rivera T, Sreih AG (2018) Pembrolizumab-associated inflammatory myopathy. Rheumatology (Oxford) 57(2):397\u2013398. https:\/\/doi.org\/10.1093\/rheumatology\/kex346","journal-title":"Rheumatology (Oxford)"},{"key":"1282_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","volume":"387","author":"J Bourgeois-Vionnet","year":"2018","unstructured":"Bourgeois-Vionnet J, Joubert B, Bernard E, Sia MA, Pante V, Fabien N, Honnorat J, Streichenberger N (2018) Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci 387:51\u201353. https:\/\/doi.org\/10.1016\/j.jns.2018.01.030","journal-title":"J Neurol Sci"},{"issue":"2","key":"1282_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"S Sheik Ali","year":"2015","unstructured":"Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA (2015) Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151(2):195\u2013199. https:\/\/doi.org\/10.1001\/jamadermatol.2014.2233","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1282_CR40","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","volume":"11","author":"C Coutzac","year":"2017","unstructured":"Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N (2017) Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct Immunopathological entities. J Crohns Colitis 11(10):1238\u20131246. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx081","journal-title":"J Crohns Colitis"},{"issue":"5","key":"1282_CR41","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","volume":"21","author":"EJ Gettings","year":"2015","unstructured":"Gettings EJ, Hackett CT, Scott TF (2015) Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 21(5):670. https:\/\/doi.org\/10.1177\/1352458514549403","journal-title":"Mult Scler"},{"issue":"8","key":"1282_CR42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73(8):928\u2013933. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1399","journal-title":"JAMA Neurol"},{"issue":"suppl 4","key":"1282_CR43","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4):iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"1282_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-020-01282-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T19:53:03Z","timestamp":1611777183000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-020-01282-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01282-w","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Lynn Vermeulen: no conflict of interest; Christophe E. Depuydt: no conflict of interest; Petra Weckx: no conflict of interest; Oliver Bechter: advisory board honoraria from Novartis, MSD, BMS, Sanofi, Merck; travel grant form MSD; Philip Van Damme: no conflict of interest; Dietmar R. Thal: Consultant honorary from GE Healthcare (UK), and Covance Laboratories (UK), speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium); Kristl G. Claeys: advisory board honoraria and research grant from Alnylam, Biogen, CSL Behring, Sanofi-Genzyme; travel reimbursement from Sanofi-Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received approval from the Ethics Committee Research UZ\/ KU Leuven.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}